Why does your weekly Ozempic shot feel like highway robbery, yet nine in ten pill bottles are dirt-cheap generics?
Policymakers are falling for a drug-pricing myth that’s been peddled for two decades. Activists scream ‘evergreening’—pharma’s supposed patent trick to squash generics and jack up prices. Sounds sinister. But here’s the acerbic truth: it’s bunk. Data shreds it.
Ever Wonder Why Generics Rule Anyway?
Take this gem from the myth-busters:
“Generics account for nine out of every 10 prescriptions filled in the United States…. If drug makers are attempting to abuse the patent system to unfairly evergreen their products, they’re failing abysmally.”
Failing abysmally. That’s dry humor gold. If Big Pharma’s gaming the system so bad, how’d generics snag 90% market share—the highest anywhere civilized? It’s not failure; it’s the system working as designed.
Lawmakers, though? They’re lapping it up. Fueled by activist whitepapers and viral tweets, they’re itching to gut patents. Why? Because myths die hard, especially when they promise cheaper drugs without the messy reality of R&D.
But wait—innovation isn’t abuse. It’s survival. Apple doesn’t drop the same iPhone yearly; they tweak cameras, batteries, screens. Ford doesn’t recycle ‘55 Thunderbirds forever. Pharma? Same deal. Post-approval, they hunt new uses, easier doses, fewer side effects. GLP-1s for diabetes and obesity? Started as daily jabs. Now? Weekly shots. Pills. No needles. Each tweak? Clinical trials. FDA scrutiny. New patents—but only for the new version.
Crucial bit: those patents don’t stretch the original’s 20-year clock. Injectable expires? Generics flood in. Oral version? Separate beast, earned its own protection. Generics hit markets 12-14 years post-approval. Clockwork. Decades of data confirm it.
Is ‘Evergreening’ Just Code for Progress?
Call it evergreening if you want drama. I call it iteration—the engine of every industry. Without it, we’d choke on daily injections forever. No obesity pills. No safer heart meds. Lawmakers weaken this? Patients get original generics on time (yay, cheap). But zero upgrades (boo, stuck in 2010).
Here’s my unique jab: this reeks of historical déjà vu. Remember the 1980s software patent wars? Critics wailed IBM and Microsoft ‘evergreened’ code tweaks to crush copycats. Result? Boom in PCs, apps, internet. Patents fueled it. Squash ‘em, and we’d still be typing on green-screens. Pharma’s rerun—except stakes are lives, not likes.
And peek ahead: AI’s next. Open-source zealots already howl at fine-tuned models as ‘evergreening.’ Weak IP here? No safer LLMs, no specialized agents—just commoditized mush. Washington’s pharma folly? Prologue to AI patent purge.
Corporate spin? Pharma loves exclusivity, sure. But activists’ data? Their own charts show generics thriving. That’s not spin; that’s inconvenient fact. Yet Congress eyes bills to trim ‘abusive’ patents. Spoiler: it backfires. Less R&D. Stale drugs. Prices? Unchanged for originals.
Look.
Short version: myth persists because outrage clicks. Reality? Boring balance—generics for old stuff, patents for new bells.
But policymakers? They’re the real risk. Buy the narrative, pass bad law, and watch innovation pack up for friendlier shores like Switzerland.
Why Does This Matter for Your Wallet?
Patients win now: cheap generics galore, plus iterative upgrades. Mess with patents? Trade fancy pills for basic ones. No brainer.
Dry laugh: if evergreening worked, why isn’t every script branded? Because it doesn’t. It’s a ghost story for hearings.
Washington, wake up. Scrutinize claims. Or risk turning gold-standard generics into innovation graveyards.
🧬 Related Insights
- Read more: Mercor’s Supply Chain Hack Exposes AI Talent Workers to Real Risks
- Read more: Remote Work’s Data Defenses: Encryption, Policies, and the GDPR Edge
Frequently Asked Questions
What is patent evergreening in drugs?
Pharma tweaking approved drugs (doses, forms) for new patents, allegedly to block generics. Data shows it doesn’t—generics enter on schedule.
Do drug patents really keep prices high forever?
No. Original patents last 20 years; generics dominate 90% of U.S. scripts after. Follow-ons protect improvements, not originals.
Will weakening patents lower drug prices?
Doubtful. You’d get generics faster (already quick), but skip upgrades like needle-free versions. Net loss for patients.
